die('
Site is under construction
Dear site users
Site is under construction.
The site will be ready in less than 24 hours.
We are sorry for the inconvenience.
www.yektaweb.com
');
Reports of Biochemistry and Molecular Biology
rbmb.net
Basic Sciences
http://rbmb.net
1
admin
2322-3480
2322-3480
10.61882/rbmb
en
jalali
1398
10
1
gregorian
2020
1
1
8
4
online
1
fulltext
en
Recombinant Expression and Purification of Extracellular Domain of the Programmed CellDeath Protein Receptor
زیست شناسی ملکولی
Molecular Biology
مقالات اصلی
Original Article
<div style="text-align: justify;"><strong>Background:</strong> The programmed cell deathprotein 1 (PD-1), which is a member of the CD28 receptor family, can negatively regulate antitumor immune responses by interacting with its ligands, PD-L1 or PD-L2. The PD-1–PD-L1 signaling pathway is a checkpoint mechanism that plays essential roles in downregulating immune responses in cancerous tissues. Thus, blocking this signaling pathway leads to enhanced antitumor immunity, potentially preventing tumor progression.<br>
<strong>Methods:</strong> We synthesized the extracellular domain of the PD-1 receptor (rPD-1) de novoby using a two-step polymerase chain reaction and the Phusion® DNA polymerase. The synthesized gene was cloned into the pET28 expression plasmid and transformed into competent <em>Escherichia coli</em>. Purification of rPD-1 was performed by metal-affinity chromatography, using a HisTrap column.Purified rPD-1 was characterized by western blotting and mass spectrometry using the SwissProt database and the Mascot program.<br>
<strong>Results:</strong> Designed and synthesized construct of rPD-1 was 500 bpin size. Analysis of the electrophoresis data of purified rPD-1 showed the presence of a protein with a molecular mass of 21 kDa. Mass spectrometry data using the SwissProt database and the Mascot program outputted the highest-scoring sequence to correspond to rPD-1.<br>
<strong>Conclusions: </strong>Synthesized de novo rPD-1 may have potential therapeutic applications in enhancing antitumor immune responses</div>
Cancer, PD-1 ligands, PD-1 receptor, Tumor immunotherapy
347
357
http://rbmb.net/browse.php?a_code=A-10-350-1&slc_lang=en&sid=1
Adish
Zhansaya
zhansaya.adish@gmail.com
100319475328460017392
100319475328460017392
Yes
National Center for Biotechnology,Kurgalzhyn road, 13/5, Astana, 010000, Kazakhstan & L.N.GumilyovEurasian National University, Satpayev st., 2, Astana, 010008, Kazakhstan.
Mukantayev
Kanatbek
mukantaev@biocenter.kz
100319475328460017393
100319475328460017393
No
National Center for Biotechnology,Kurgalzhyn road, 13/5, Astana, 010000, Kazakhstan
Tursunov
Kanat
kanat_tka@mail.ru
100319475328460017394
100319475328460017394
No
National Center for Biotechnology,Kurgalzhyn road, 13/5, Astana, 010000, Kazakhstan
Ingirbay
Bakhytkali
bakytkali.kabi@mail.ru
100319475328460017395
100319475328460017395
No
National Center for Biotechnology,Kurgalzhyn road, 13/5, Astana, 010000, Kazakhstan
Kanayev
Darkhan
dake_2008z@mail.ru
100319475328460017396
100319475328460017396
No
National Center for Biotechnology,Kurgalzhyn road, 13/5, Astana, 010000, Kazakhstan
Kulyyassov
Arman
akulyyasov@gmail.com
100319475328460017397
100319475328460017397
No
National Center for Biotechnology,Kurgalzhyn road, 13/5, Astana, 010000, Kazakhstan
Tarlykov
Pavel
tarlykov@biocenter.kz
100319475328460017398
100319475328460017398
No
National Center for Biotechnology,Kurgalzhyn road, 13/5, Astana, 010000, Kazakhstan
Mukanov
Kasym
mukanov@biocenter.kz
100319475328460017399
100319475328460017399
No
National Center for Biotechnology,Kurgalzhyn road, 13/5, Astana, 010000, Kazakhstan
Ramankulov
Yerlan
ramanculov@biocenter.kz
100319475328460017400
100319475328460017400
No
National Center for Biotechnology,Kurgalzhyn road, 13/5, Astana, 010000, Kazakhstan